Payment overview · 2025
General Payments
$758.99
11 reported records · 5 companies
Healthcare provider profile · identity verified
Sandra L Salinas, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · RIO GRANDE CITY, TX · NPI 1912662701
Verified facts
What the public records show
CMS Open Payments records show Sandra L Salinas, NP received $758.99 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 88.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $673.04 | 88.7% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.70 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.97 | 2.9% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $18.85 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.43 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $732.29 | 10 |
| Education | $26.70 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $406.76 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $43.56 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.70 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
132 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 369 | 123 |
| Metformin Hcl | Metformin Hcl | 265 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 259 | 92 |
| Jardiance | Empagliflozin | 219 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 206 | 74 |
| Losartan Potassium | Losartan Potassium | 203 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 195 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 65 |
| Alprazolam | Alprazolam | 183 | 46 |
| Tramadol Hcl | Tramadol Hcl | 170 | 53 |
| Ibuprofen | Ibuprofen | 158 | 82 |
| Azithromycin | Azithromycin | 155 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 136 | 47 |
| Omeprazole | Omeprazole | 136 | 47 |
| Ozempic | Semaglutide | 132 | 26 |
| Lisinopril | Lisinopril | 130 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 65 |
| Diclofenac Sodium | Diclofenac Sodium | 109 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 88 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 87 | 29 |
| Montelukast Sodium | Montelukast Sodium | 85 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 35 |
| Alendronate Sodium | Alendronate Sodium | 70 | 28 |
| Trazodone Hcl | Trazodone Hcl | 63 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 20 |
| Furosemide | Furosemide | 59 | 25 |
| Ofloxacin | Ofloxacin | 59 | 49 |
| Sertraline Hcl | Sertraline Hcl | 57 | 23 |
| Linzess | Linaclotide | 56 | 15 |
| Meclizine Hcl | Meclizine Hcl | 55 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 12 |
| Fluconazole | Fluconazole | 52 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 16 |
| Spironolactone | Spironolactone | 52 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | suppressed |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Mupirocin | Mupirocin | 48 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 20 |
| Trulicity | Dulaglutide | 47 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 17 |
| Januvia | Sitagliptin Phosphate | 43 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 17 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 32 |
| Famotidine | Famotidine | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 25 |
| Memantine Hcl | Memantine Hcl | 37 | 12 |
| Simvastatin | Simvastatin | 36 | 13 |
| Allopurinol | Allopurinol | 34 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Primidone | Primidone | 30 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 15 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 22 |
| Cilostazol | Cilostazol | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Naproxen | Naproxen | 24 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 20 |
| Ciclopirox | Ciclopirox | 22 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | 13 |
| Nystatin | Nystatin | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | 14 |
| Baclofen | Baclofen | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 12 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Eliquis | Apixaban | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $758.99 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, ImmunoCAP, LOKELMA, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error